Drug Trial Radar · NCT05230537
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Feb 17, 2022
Primary completion
Aug 19, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD.
Conditions
- Age-Related Macular Degeneration
Interventions
Iptacopan (LNP023)Drug
oral capsules
PlaceboDrug
oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of new incomplete retinal pigment epithelium & outer retinal atrophy or late age-related macular degeneration (AMD) in the early/intermediate AMD eye as determined by optical coherence tomography (OCT) & supported by multimodal imagingTime frame: Baseline/Day 1 through Month 24
Locations
28 sites in 4 countries. Site status is shown where the registry gives one.
Retina Consultants of Orange County
Fullerton, California
Salehi Retina Institute
Huntington Beach, California
Martel Eye Medical Group
Rancho Cordova, California
Retinal Consultants Medical Group Inc
Sacramento, California
California Retina Consultants
Santa Barbara, California
Southwest Retina Research Center
Durango, Colorado
Advanced Research LLC
Deerfield Beach, Florida
Retina Center Of South Florida
Delray Beach, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Midwest Eye Institute
Carmel, Indiana
Retina Associates New Orleans
Metairie, Louisiana
Retina Care Center
Baltimore, Maryland
Opthamalic Consultants of Boston
Boston, Massachusetts
Envision Ocular LLC
Bloomfield, New Jersey
Duke Eye Center
Durham, North Carolina
Retina Northwest PC
Portland, Oregon
Charles Retina Institute
Germantown, Tennessee
Austin Research Center for Retina
Austin, Texas
Retina Consultants TX Rsrch Ctr
Bellaire, Texas
Retina Foundation
Dallas, Texas
Texas Retina Associates
Fort Worth, Texas
Retina Consultants of Houston PA
Houston, Texas
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Harbin, Heilongjiang, China
Novartis Investigative Site
Tianjin, Tianjin Municipality, China
Emanuelli Research and Development Center LLC
Arecibo, Puerto Rico
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Southampton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.